The Cooper Companies (NASDAQ: COO) — Perfil da empresa, notícias e dados financeiros
The Cooper Companies is a global medical device company that operates through two main business units, CooperVision and CooperSurgical.
The Cooper Companies
The Cooper Companies is a global medical device company that operates through two main business units, CooperVision and CooperSurgical. CooperVision specializes in contact lens manufacturing, producing a broad range of single-use, daily, and monthly soft contact lenses, as well as specialized pediatric myopia management products. CooperSurgical focuses on women's healthcare and fertility, offering medical devices, surgical equipment, intrauterine contraceptives, and assisted reproductive technologies including cell culture media and genetic testing services for in vitro fertilization clinics. Headquartered in San Ramon, California, the company maintains manufacturing, research, and distribution infrastructure across North America, Europe, and Asia-Pacific.
Resumo
Operações
Produtos e/ou serviços de The Cooper Companies
- Contact Lenses: Development and manufacture of soft contact lenses including spherical, toric, and multifocal designs under brands such as Biofinity, MyDay, and Clariti 1-day for vision correction across daily, two-week, and monthly replacement schedules.
- Myopia Management: Provision of specialized pediatric vision care and myopia control solutions, including MiSight 1 day soft contact lenses and orthokeratology products designed to slow the progression of myopia in young patients.
- Fertility Solutions: Supply of assisted reproductive technology products for fertility clinics worldwide, including specialized culture media, micromanipulation tools, lab equipment, and automated sperm selection systems used in in vitro fertilization procedures.
- Reproductive Genetics: Delivery of preimplantation genetic testing services and genomic analysis tools that enable fertility centers and healthcare providers to screen embryos for chromosomal abnormalities and genetic disorders prior to clinical transfer.
- Contraceptive Devices: Manufacture and distribution of long-acting reversible contraceptive solutions, including the PARAGARD non-hormonal copper intrauterine device (IUD), serving healthcare providers, hospital surgical centers, and women's health practices globally.
- Surgical Medical Equipment: Production of specialized surgical instruments, diagnostic equipment, and medical devices for women's healthcare, including uterine manipulators, tissue management tools, and laparoscopic accessories for hospital operating rooms.
equipe executiva do The Cooper Companies
- Albert G. White IIIPresident, CEO & Non-Independent Director
- Brian G. AndrewsExecutive VP, CFO & Principal Accounting Officer
- Daniel G. McBrideExecutive VP, COO General Counsel & Secretary
- Holly R. SheffieldPresident of CooperSurgical, Inc.
- Gerard H. Warner IIIPresident of CooperVision, Inc.
- Kim DuncanVice President of Investor Relations & Risk Management
Histórico de dividendos
Dividendos por ação pagos pela The Cooper Companies , por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2023 | — | — | — | $0.0150 |
| FY2022 | — | — | — | $0.0150 |
| FY2021 | — | — | — | $0.0150 |
| FY2020 | — | — | — | $0.0150 |
| FY2019 | — | — | — | $0.0150 |
Principais indicadores financeiros
Resultados divulgados pela The Cooper Companies , em USD.
- Cap. de mercado
- 11,3 bi
- Receita (TTM)
- 4,2 bi
- P/L
- 20.4
- LPA (diluído, TTM)
- 2.9
- Dividend yield
- —
- Margem de lucro
- 13.5%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 4,1 bi | 682,9 mi | 374,9 mi | |
| 3,9 bi | 705,7 mi | 392,3 mi | |
| 3,6 bi | 533,1 mi | 294,2 mi | |
| 3,3 bi | 507,6 mi | 385,8 mi |